gastric cancer
Conditions
Interventions
single group:anti-PD1 antibody,Smart-T
Sponsors
The Affiliated Hospital of Nanjing University Medical School
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Aged >= 18 years. 2. Histologically or cytologically confirmed gastric cancer with malignant peritoneal effusion or peritoneal metastasis. 3. Patients with gastric cancer who failed previous standard treatment, or who refused follow-up chemotherapy, expected to survive for more than 8 weeks. 4. The patient has not previously received immunotherapy. 5. Appropriate protective measures (contraception or other methods of birth control) should be taken before and during the trial. 6. Informed consent has been signed. 7. Ability to follow study protocol and follow up procedures.
Exclusion criteria
Exclusion criteria: 1. Previously received tumor chemotherapy, radiotherapy and other anti-tumor treatment within one month; Received any form of immunotherapy within the previous 3 months. 2. Patients had a history of other tumors, except for cervical carcinoma in situ, treated squamous cell carcinoma or bladder epithelial neoplasm (Ta and TIS), or other malignancies that had undergone radical treatment (at least 5 years prior to enrollment). 3. Leukocyte count 3 x Upper normal value,Total bilirubin. 5. Creatinine clearance = level 2 of NCI-CTC, Third edition). 8. Patients have HIV infection, HCV infection, uncontrolled coronary artery disease or asthma, uncontrollable cerebrovascular disease or other diseases that the investigator believes are unincorporated. 9. Pregnant, lactating women. Women of childbearing age must be tested negative for pregnancy test within 7 days prior to enrollment. 10. Drug abuse, clinical or psychological or social factors affect informed consent or research implementation. 11. Those who may be allergic to research drugs. 12. Patients who are unable to perform lymphocyte separation or peripheral venous access cannot be opened. 13. Any uncertainty that affects patient safety or compliance. 14. Feasibility assessment during the screening process showed that T lymphocytes were not sufficient for CD3 and IL-2 stimulation signals to trigger a cell proliferation response.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| OS; | — |
Secondary
| Measure | Time frame |
|---|---|
| Imaging evaluation;Ascites volume;improvement of quality of life;safety evaluation; | — |
Countries
China
Contacts
Public ContactJia Wei
The Affiliated Hospital of Nanjing University Medical School
Outcome results
None listed